Literature DB >> 264797

Repeated chlorpromazine administration increases a behavioural response of rats to 5-hydroxytryptamine receptor stimulation.

A R Green.   

Abstract

1 The hyperactivity syndrome produced in rats by administration of tranylcypromine (20 mg/kg i.p.) followed 30 min later by L-tryptophan (50 mg/kg i.p.) is generally considered to be due to increased 5-hydroxytryptamine (5-HT) functional activity. It is inhibited by chlorpromazine (30 mg/kg i.p.) injected 60 min before the tranylcypromine. However, chlorpromazine injection for 4 days either at a dose of 30 mg/kg once daily or 5 mg/kg twice daily results in an enhanced hyperactivity response to tranylcypromine and L-tryptophan administration 24 h after the final dose of chlorpromazine. 2 One injection of chlorpromazine (30 mg/kg) did not produce enhancement 24 h later and the inhibition of the tranylcypromine/L-tryptophan hyperactivity observed after acute chlorpromazine injection was seen if the rats were given tranylcypromine and L-tryptophan 1 h after the fourth chlorpromazine (30 mg/kg) dose. 3 Chlorpromazine (30 mg/kg) once daily or 5 mg/kg twice daily for 4 days resulted in rats displaying enhanced behavioral responses to the suggested 5-HT agonist 5-methoxy N,N-dimethyltryptamine (2 mg/kg) on day 5. 4 Chlorpromazine (30 mg/kg) once daily for 4 days produces a slight increase in brain 5-hydroxytryptamine (5-HT) concentration on day 5, but no difference in the rate of brain 5-HT synthesis or the rate of 5-HT accumulation after tranylcypromine and L-tryptophan administration. 5. There is some evidence that chlorpromazine blocks 5-HT receptors. It has also been observed that several other neuroleptic drugs do not produce enhanced 5-HT responses after repeated administration. It is suggested therefore that the enhanced behavioural response to 5-HT receptor stimulation following repeated chlorpromazine administration may be because this drug blocks 5-HT receptors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 264797      PMCID: PMC1667726          DOI: 10.1111/j.1476-5381.1977.tb07501.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Behavioral supersensitivity to 5-hydroxytryptophan induced by chronic methysergide pretreatment.

Authors:  H L Klawans; D J D'Amico; B C Patel
Journal:  Psychopharmacologia       Date:  1975-11-21

2.  The effects of chlorpromazine on serum tryptophan, brain tryptophan uptake and brain serotonin synthesis in the rat.

Authors:  D A Bender
Journal:  Biochem Pharmacol       Date:  1976-08-01       Impact factor: 5.858

3.  The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.

Authors:  A R Green; D G Grahame-Smith
Journal:  Neuropharmacology       Date:  1974-11       Impact factor: 5.250

4.  Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol.

Authors:  G Gianutsos; R B Drawbaugh; M D Hynes; H Lal
Journal:  Life Sci       Date:  1974-03-01       Impact factor: 5.037

5.  In vivo measurement of brain serotonin turnover.

Authors:  N H Neff; T N Tozer
Journal:  Adv Pharmacol       Date:  1968

6.  Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain.

Authors:  G Curzon; A R Green
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

Review 7.  Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine.

Authors:  A R Green; D G Grahame-Smith
Journal:  Nature       Date:  1976-04-08       Impact factor: 49.962

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  Serotonin-sensitive adenylate cyclase activity of immature rat brain.

Authors:  K von Hungen; S Roberts; D F Hill
Journal:  Brain Res       Date:  1975-02-07       Impact factor: 3.252

10.  Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine.

Authors:  M E Trulson; E E Eubanks; B L Jacobs
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

View more
  3 in total

1.  A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists.

Authors:  A R Green; J E Hall; A R Rees
Journal:  Br J Pharmacol       Date:  1981-07       Impact factor: 8.739

Review 2.  Sexual behavior of the male schizophrenic: the impact of illness and medications.

Authors:  J N Nestoros; H E Lehmann; T A Ban
Journal:  Arch Sex Behav       Date:  1981-10

3.  Increased platelet membrane [3H]-LSD binding in patients on chronic neuroleptic treatment.

Authors:  M Schächter; D P Geaney; D G Grahame-Smith; P J Cowen; J M Elliott
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.